Welcome to our dedicated page for Viaderma news (Ticker: VDRM), a resource for investors and traders seeking the latest updates and insights on Viaderma stock.
ViaDerma, Inc. (VDRM) is a specialty pharmaceutical company focused on transdermal drug delivery and topical antibiotic products, and its news flow reflects this focus. Company updates highlight developments around its tetracycline-based topical antibiotic, Vitastem, and Vitastem Ultra, as well as broader product pipeline initiatives in areas such as anti-aging skincare, pain management, hair-loss treatments, sexual wellness products, and CBD-based formulations.
News releases frequently cover ViaDerma’s international expansion, including shipments of its flagship topical antibiotic to Nigeria, the opening of a satellite office in Dubai, and the finalization of distribution agreements in Dubai to reach markets in the Middle East and Eastern Europe. Additional coverage includes progress on product registration in India and the start of registration processes in countries such as Kenya, Namibia, and Tanzania, along with plans for further applications across Africa, Europe, and the Middle East.
Investors and observers can also find financial and operational updates in ViaDerma’s news, such as quarterly and half-year results, changes in cash position, and commentary on profitability and liabilities. The company has issued statements about remaining fully operational, working to complete overdue financial reports, and exploring strategic options related to its public status on OTC Markets and the OTC Expert Market.
Other recurring themes in ViaDerma news include stability testing for Vitastem Ultra, licensing and regulatory milestones, staffing and organizational growth, and discussions with potential partners such as healthcare organizations and government-related entities. For anyone tracking VDRM, the news feed offers insight into the company’s product progress, geographic expansion, financial condition, and evolving regulatory and market strategy.
ViaDerma, Inc. (OTC Pink: VDRM) has finalized a ten-year licensing agreement worth $12 million with a company in Dubai, granting exclusive rights to sell its products in the Middle East. The first payment of $600,000 is expected by August 5, 2021. Additionally, ViaDerma's partnership with a home health wound care network has expanded across nine states, generating $45,000 monthly in royalties. The company plans to hire an auditing firm within 30 to 60 days for financial audits necessary for an OTCQB listing application later this year.
ViaDerma, Inc. (OTC: VDRM) has expanded its licensing agreement with a home health wound care network, increasing monthly royalties from $35,000 to $40,000 due to the addition of two states. Expected revenue could reach $80,000 monthly by year-end. The company is also set to generate approximately $600,000 annually from a new limb salvage campaign. Additionally, President Dr. Chris Otiko will finalize a $12 million licensing agreement in Dubai by June 25, with an initial payment of $600,000 due upon conclusion.
ViaDerma, Inc. (OTC Pink: VDRM) is nearing a major order for its wound care product, Vitastem, from a significant healthcare network after successful testing. This order is projected to flow into hundreds of hospitals and nursing homes. Additionally, ViaDerma is expanding its licensing agreement to eight states, earning $5,000 per month for each state. The company plans to file its first quarter financials by May 17 and is addressing its temporary status with OTC Markets to return to Current Status.
ViaDerma, Inc. (OTC Pink: VDRM) reported substantial revenue growth for Q1 2021, expecting revenues to exceed $113,000, a remarkable increase of 5000% compared to $2,133 in Q1 2020. Online retail sales contributed over $23,000, up 978% year-over-year, while a licensing agreement brought in $90,000. The company eliminated all toxic convertible debt and is now debt-free, planning to self-fund future operations. ViaDerma seeks to list on OTCQB by securing audited financials and independent directors, while focusing on institutional clients for future sales.
ViaDerma, Inc. (VDRM) announced on March 16, 2021, that it has eliminated over $869,900 in toxic convertible debt, becoming completely debt-free. The company settled with creditors to convert outstanding notes into only 70 million shares, significantly reducing potential shareholder dilution. CEO Dr. Chris Otiko emphasized that this milestone allows the company to focus on increasing sales and self-funding future operations. Additionally, ViaDerma's licensing agreement for its Vitastem product has generated $30,000 in monthly revenue across six states, with planned expansions in the near future.